Oliver Philps

Medicinal Chemistry and Competitive Intelligence

Oliver Philps is an experienced medicinal chemist who has worked for a diverse range of biotechnology and pharmaceutical companies throughout his career (including Vertex Pharmaceuticals, GSK, AstraZeneca and Eisai). He has extensive experience in progressing compounds from hit-to-lead through to lead optimisation and candidate selection in the fields of oncology, inflammation and CNS. In addition, Oliver has a passion for understanding ‘the bigger picture’ of the pharmaceutical industry and is particularly interested in competitive intelligence.

How GLP-1 Receptor Agonists Evolved from Diabetes to Weight Loss Treatments | Flash Talk Highlights

Peptidic GLP-1R agonists have received significant media coverage over the past year for their astounding efficacy in several indications. While most of the recent fanfare has been related to their role in weight loss, GLP-1R agonists have been a mainstay of the type 2 diabetes treatment landscape for the past 2 decades. GLP-1R agonists have also recently shown efficacy in reducing heart disease risk and treating certain chronic kidney diseases. Here’s a recap of the March 14th, 2024, Flash Talk, from Oliver Philps.

Article

How GLP-1 Receptor Agonists Evolved from Diabetes Treatments to Weight Loss Treatments

Peptidic GLP-1R agonists have received significant media coverage over the past year for their astounding efficacy in several indications. GLP-1R agonists now appear to be efficacious in reducing heart disease risk and in treating certain chronic kidney diseases, expanding their likely future use. This review by Oliver Philps provides an overview of GLP-1 agonists and where they fit in the treatment of diabetes, how the peptide drugs evolved over time to today’s weight loss medications, and what to expect next...

Article

Join the Drug Hunter Mailing List

to get free content and resources weekly. Trusted by >8,000 drug hunters worldwide. Unsubscribe anytime.